From BACE1 Inhibitor to Multifunctionality of Tryptoline and Tryptamine Triazole Derivatives for Alzheimer’s Disease

From BACE1 Inhibitor to Multifunctionality of Tryptoline and Tryptamine Triazole Derivatives for Alzheimer’s Disease

Efforts to discover new drugs for Alzheimer’s disease emphasizing multiple targets was conducted seeking to inhibit amyloid oligomer formation and to prevent radical formation. The tryptoline and tryptamine cores of BACE1 inhibitors previously identified by virtual screening were modified <em...

Full description

Bibliographic Details
Main Authors:	Jutamas Jiaranaikulwanitch, Piyarat Govitrapong, Valery V. Fokin, Opa Vajragupta
Format:	Article
Language:	English
Published:	MDPI AG 2012-07-01
Series:	Molecules
Subjects:	multifunction drugs BACE1 inhibitor anti-amyloid aggregation chelator antioxidant neuroprotection
Online Access:	http://www.mdpi.com/1420-3049/17/7/8312

Similar Items

Novel Multifunctional Ascorbic Triazole Derivatives for Amyloidogenic Pathway Inhibition, Anti-Inflammation, and Neuroprotection
by: Jutamas Jiaranaikulwanitch, et al.
Published: (2021-03-01)

Lead discovery of a guanidinyl tryptophan derivative on amyloid cascade inhibition
by: Suwanttananuruk Piyapan, et al.
Published: (2020-06-01)

Role of BACE1 in Alzheimer’s synaptic function
by: Brati Das, et al.
Published: (2017-08-01)

Tacrine, trolox and tryptoline as lead compounds for the design and synthesis of multi-target drugs for Alzheimer's disease therapy
by: Teponnou, Gerard A. Kenfack
Published: (2016)

BACE-1 and γ-Secretase as Therapeutic Targets for Alzheimer’s Disease
by: Miguel A. Maia, et al.
Published: (2019-03-01)

Development and Structural Modification of BACE1 Inhibitors
by: Ting Gu, et al.
Published: (2016-12-01)

The BACE‐1 inhibitor CNP520 for prevention trials in Alzheimer's disease
by: Ulf Neumann, et al.
Published: (2018-11-01)

BACE1 Function and Inhibition: Implications of Intervention in the Amyloid Pathway of Alzheimer’s Disease Pathology
by: Gerald Koelsch
Published: (2017-10-01)

Decreased expression of GGA3 Protein in Alzheimer's disease frontal cortex and increased co-distribution of BACE with the amyloid precursor protein
by: Claudia Santosa, et al.
Published: (2011-07-01)

Liraglutide Suppresses Tau Hyperphosphorylation, Amyloid Beta Accumulation through Regulating Neuronal Insulin Signaling and BACE-1 Activity
by: Salinee Jantrapirom, et al.
Published: (2020-03-01)

Design, Synthesis and Evaluation of Novel Tacrine-Ferulic Acid Hybrids as Multifunctional Drug Candidates against Alzheimer’s Disease
by: Yingbo Fu, et al.
Published: (2016-10-01)

Naturally Inspired Molecules as Multifunctional Agents for Alzheimer’s Disease Treatment
by: Angela Rampa, et al.
Published: (2016-05-01)

Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
by: Judite R. M. Coimbra, et al.
Published: (2018-05-01)

Glycosaminoglycans from <i>Litopenaeus vannamei</i> Inhibit the Alzheimer’s Disease β Secretase, BACE1
by: Courtney J. Mycroft-West, et al.
Published: (2021-04-01)

Synthesis and Evaluation of Paeonol Derivatives as Potential Multifunctional Agents for the Treatment of Alzheimer’s Disease
by: An Zhou, et al.
Published: (2015-01-01)

Design, synthesis and evaluation of novel cinnamic acid derivatives bearing N-benzyl pyridinium moiety as multifunctional cholinesterase inhibitors for Alzheimer’s disease
by: Jin-Shuai Lan, et al.
Published: (2017-01-01)

Electroacupuncture reduces Aβ production and BACE1 expression in SAMP8 mice
by: Weiguo eDong, et al.
Published: (2015-07-01)

Triptolide treatment reduces Alzheimer’s disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD
by: Qi Wang, et al.
Published: (2014-12-01)

A Tale of Two Drug Targets: The Evolutionary History of BACE1 and BACE2
by: Christopher eSouthan, et al.
Published: (2013-12-01)

Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer’s disease mutations but not by inhibition of BACE1
by: Erik C. B. Johnson, et al.
Published: (2020-09-01)

Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study
by: Maarten Timmers, et al.
Published: (2018-08-01)

BACE1 (β-secretase) knockout mice do not acquire compensatory gene expression changes or develop neural lesions over time
by: Yi Luo, et al.
Published: (2003-10-01)

Developing BACE-1 inhibitors for FXS
by: Cara J Westmark, et al.
Published: (2013-05-01)

Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models
by: Teemu Natunen, et al.
Published: (2016-01-01)

Design, Synthesis and Biological Evaluation of 2,4-Disubstituted Pyrimidine Derivatives: Multifunctional Candidates as Potential Treatment Options for Alzheimer’s Disease
by: Mohamed, Tarek
Published: (2011)

Design, Synthesis and Biological Evaluation of 2,4-Disubstituted Pyrimidine Derivatives: Multifunctional Candidates as Potential Treatment Options for Alzheimer’s Disease
by: Mohamed, Tarek
Published: (2011)

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study
by: Gerald Novak, et al.
Published: (2020-05-01)

Expression analysis of beta-secretase 1 (BACE1) enzyme in peripheral blood of patients with Alzheimer\'s disease
by: Alireza Vakilian, et al.
Published: (2019-06-01)

Bace1 activity impairs neuronal glucose metabolism: rescue by beta-hydroxybutyrate and lipoic acid
by: John A Findlay, et al.
Published: (2015-10-01)

Fluorinated Molecules and Nanotechnology: Future ‘Avengers’ against the Alzheimer’s Disease?
by: Meghna Dabur, et al.
Published: (2020-04-01)

The emerging role of β-secretases in cancer
by: Francesco Farris, et al.
Published: (2021-04-01)

A Glycosaminoglycan Extract from <i>Portunus pelagicus</i> Inhibits BACE1, the β Secretase Implicated in Alzheimer’s Disease
by: Courtney J. Mycroft-West, et al.
Published: (2019-05-01)

Presenilin-1 interacts directly with the β-site amyloid protein precursor cleaving enzyme (BACE1)
by: Sébastien S Hébert, et al.
Published: (2003-08-01)

Characterization of Diagnostic Tools and Potential Treatments for Alzheimer’s Disease : PET ligands and BACE1 inhibitors
by: Jeppsson, Fredrik
Published: (2016)

Use of Peptides for the Management of Alzheimer’s Disease: Diagnosis and Inhibition
by: Mohammad H. Baig, et al.
Published: (2018-02-01)

The Identification of Biochanin A as a Potent and Selective β-Site App-Cleaving Enzyme 1 (Bace1) Inhibitor
by: Kumju Youn, et al.
Published: (2016-10-01)

pHluorin-BACE1-mCherry Acts as a Reporter for the Intracellular Distribution of Active BACE1 In Vitro and In Vivo
by: Lu Zhao, et al.
Published: (2019-05-01)

Biological evaluation and in silico docking study of γ-linolenic acid as a potential BACE1 inhibitor
by: Kumju Youn, et al.
Published: (2014-09-01)

CSF levels of the BACE1 substrate NRG1 correlate with cognition in Alzheimer’s disease
by: François Mouton-Liger, et al.
Published: (2020-07-01)

Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease
by: Michael F. Egan, et al.
Published: (2019-08-01)